Ashraf Almomani

Ashraf Almomani

Auto-generated profile, based on publicly available information

Ashraf Almomani

Department of Gastroenterology, University of Missouri, Columbia, Missouri, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2022 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
AAAshraf Almomani
Ashraf Almomani
PKPrabhat Kumar
Prabhat Kumar
SOSomtochukwu Onwuzo
Somtochukwu Onwuzo
ABAntoine Boustany
Antoine Boustany
EKEduard Krishtopaytis
Eduard Krishtopaytis
IAImad Asaad
Imad Asaad
Backgrounds: Nonalcoholic fatty liver disease (NAFLD) is linked to obesity and metabolic syndrome conditions. However, a subset of NAFLD patients express a normal or low body mass index (lean NAFLD [L‐NAFLD]). Our aim is to compare the prevalence of L‐NAFLD to the obesity‐associated NAFLD in the United States by assessing prevalence, potential risk factors, liver‐related complications, and coronary artery disease outcomes.Methodology: A multicenter database (Explorys Inc.) of >70 million patients across the United States was screened. A cohort of patients with “nonalcoholic fatty liver” between 1999 and 2021 was identified. Two sub‐cohorts of NAFLD patients were identified: those with a body mass index (BMI) < 25 kg/m2 (L‐NAFLD) and those with a BMI > 30 kg/m2 (obesity‐associated NAFLD). We excluded patients with age <18 and those who have viral hepatitis, hemochromatosis, Wilson's disease, biliary cirrhosis, alcoholic liver disease, cystic fibrosis, alpha‐1‐antitrypsin deficiency, and autoimmune hepatitis. Multivariate analysis was performed to adjust for confounders.Results: 68 892 260 individuals were screened. NAFLD prevalence was four per 100 000, and L‐NAFLD prevalence was 0.6 per 100 000. Compared with those without, patients with L‐NAFLD tended to be older (OR 2.16), females (OR 1.28), and smokers (OR 4.67) and of Asian race (OR 2.12). L‐NAFLD patients were more likely to have acute coronary syndromes (OR 30.00) and metabolic syndrome (OR 2.31) despite the normal/low BMI. Esophageal varices and hepatocellular carcinoma risks were high in both cirrhosis patients.Conclusion: This is the largest study to assess L‐NAFLD prevalence in the United States. L‐NAFLD are at a significantly higher risk for acute coronary syndromes, esophageal varices, and hepatocellular carcinoma.

23 January 2023 in Cureus
Verified
Journal Article
Open access
PDF file
SOSomtochukwu Onwuzo
Somtochukwu Onwuzo
ABAntoine Boustany
Antoine Boustany
HZHadi Khaled Abou Zeid
Hadi Khaled Abou Zeid
AHAsif A. Hitawala
Asif A. Hitawala
AAAshraf Almomani
Ashraf Almomani
IAImad Asaad
Imad Asaad
Background and aim Proton pump inhibitor (PPI) is a heavily prescribed medication in the United States that is used to treat several gastrointestinal disorders. Although it has been considered to be safe compared to other medications, multiple gastrointestinal side effects have been reported. These effects of PPIs might stem from the progressive alteration of the intestinal microbiome. Patients with inflammatory bowel disease (IBD) using PPI are also seen to be less likely to achieve remission. However, in the current literature, there is very little evidence of the risk of developing IBD in patients who have been using PPIs. Therefore, our aim was to perform a cross-sectional population-based study with in-depth analysis to assess the prevalence and risk factors of IBD amongst PPI users in the United States. Methodology A validated multicenter and research platform database of more than 360 hospitals from 26 different healthcare systems across the United States was utilized to construct this study. A cohort of patients with a diagnosis of ulcerative colitis (UC) and Crohn’s disease (CD) between 1999-2022 was identified using the Systematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT). Patients aged 18 to 65 years were included. We excluded any individual who had a diagnosis of chronic liver disease, autoimmune disease (excluding IBD), or cancer. The risk of IBD was calculated using a multivariate regression analysis to account for potential confounders including non-steroidal anti-inflammatory drugs (NSAIDs) use, smoking, patients who have had a diagnosis of alcoholism, gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), and metabolic syndrome. A two-sided P-value <0.05 was considered statistically significant, and all statistical analyses were performed using R version 4.0.2 (R Foundation for Statistical Computing, Vienna, Austria, 2008). Results A total of 79,984,328 individuals were screened in the database and 45,586,150 patients were selected in the final analysis after accounting for inclusion and exclusion criteria. Using multivariate regression analysis, the risk of developing UC and CD was calculated. The odds of having UC amongst patients on PPI was 2.02 (95%CI 1.98-2.06), P-value <0.001. Similarly, the odds of having CD were high amongst PPI users (OR 2.79, 95%CI 2.75-2.84), P- value <0.001 Conclusion Our study demonstrates that patients on PPIs are frequently found to have UC and CD even when adjusting for common risk factors. Hence, we urge clinicians to be aware of this association in order to limit unnecessary prescriptions of PPIs, especially for patients who are at risk for autoimmune diseases.

1 September 2023 in Arquivos de Gastroenterologia
Verified
Journal Article
Open access
ABAntoine Boustany
Antoine Boustany
SOSomtochukwu Onwuzo
Somtochukwu Onwuzo
HZHadi Khaled Abou Zeid
Hadi Khaled Abou Zeid
AAAshraf Almomani
Ashraf Almomani
IAImad Asaad
Imad Asaad
Background: During the past decade, Clostridioides difficile infection (CDI) has become the most common cause of antibiotic-associated diarrhea. Several risk factors have been implicated. Scattered evidence about the association of CDI with antidepressant medications use exists in the literature so far. Therefore, we aim to investigate whether the risk of developing CDI is increased in hospitalized patients using antidepressant medications. Methods: Patients who were hospitalized were included in our cohort. We excluded individuals aged less than 18 years. A multivariate regression analysis was performed to calculate the risk of CDI accounting for potential confounders. Results: The risk of CDI in hospitalized patients was increased in individuals diagnosed with inflammatory bowel disease (OR: 4.44; 95%CI: 4.35-4.52), and in patients using clindamycin (OR: 1.55; 95%CI: 1.53-1.57), beta-lactam antibiotics (OR: 1.62; 95%CI: 1.60-1.64), PPI (OR: 3.27; 95%CI: 3.23-3.30), trazodone (OR: 1.31; 95%CI: 1.29-1.33), nortriptyline (OR: 1.25; 95%CI: 1.21-1.28), and mirtazapine (OR: 2.50; 95%CI: 2.46-2.54). After controlling for covariates, the risk of CDI was not increased in patients who were taking fluoxetine (OR: 0.94; 95%CI: 0.92-0.96). Conclusion: In contrary to fluoxetine; mirtazapine, nortriptyline, and trazodone were associated with increased risk of CDI in hospitalized patients.


20 April 2026 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
AAAkram I. Ahmad
Akram I. Ahmad
ZAZaid Ansari
Zaid Ansari
TATasneem Jamal Al-Din
Tasneem Jamal Al-Din
MNMichael A. Nicolas
Michael A. Nicolas
DRDavid Restrepo
David Restrepo
ARAsad Ur Rahman
Asad Ur Rahman
INTRODUCTION: Obesity is highly prevalent among US adults and is linked to a higher risk of colorectal neoplasia, making it essential to optimize colonoscopy for this population. However, comparative data guiding colonoscope selection in obese individuals remain limited. METHODS: A randomized equivalence clinical trial conducted at 2 Cleveland Clinic Florida locations included patients aged 18 years or older with a body mass index of ≥30 kg/m 2 , scheduled for screening or surveillance colonoscopy. The primary outcome was a composite of successful cecal intubation within 10 minutes without the need for scope exchange. Participants were randomly assigned in a 1:1 ratio to slim (pediatric) or adult colonoscopes. RESULTS: A total of 245 participants entered the study protocol between January and September 2025. The primary endpoint was achieved in 94.3% of the slim colonoscope group and 92.6% of the adult colonoscope group, resulting in an unadjusted absolute risk difference of 1.7% (95% CI: −4.3% to 8.2%). This confirms equivalence within the predefined ±10% margin. After adjusting for sex, body mass index, bowel preparation quality, diverticulosis, and surgical history, the adjusted risk difference was 2.6% (95% CI: −4.3% to 8.6%). Secondary outcomes, including insertion time, withdrawal time, overall cecal intubation rate, terminal ileum intubation rate, adenoma detection rate, and use of ancillary maneuvers, were similar between the study groups. DISCUSSION: Among expert endoscopists, slim and adult colonoscopes are equivalent in facilitating nondifficult colonoscopy in obese patients, with a trend toward improved performance using the slim colonoscope.

6 July 2023 in Gastroenterology
Verified
Journal Article
Closed access
ABAntoine Boustany
Antoine Boustany
SOSomtochukwu Onwuzo
Somtochukwu Onwuzo
KAKhaled Alsabbagh Alchirazi
Khaled Alsabbagh Alchirazi
SSSimon P. Abi Saleh
Simon P. Abi Saleh
SHSammy Hanna
Sammy Hanna
IAImad Asaad
Imad Asaad